EDIT Editas Medicine, Inc.

EDIT financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1650664 Exchange: Nasdaq SIC: 2836 (Biological Products, (No Diagnostic Substances)) Latest filing: 10-Q filed Nov 9, 2026 Data checked: Nov 10, 2026
Showing 3 of 12 annual and 0 of 47 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$191.38M (Jun 2025)
Industry (SIC)
2836 Biological Products, (No Diagnostic Substances)
Incorporated
DE
Fiscal Year End
December (1231)
Phone
617-401-9000
EIN
464097528
Headquarters
CAMBRIDGE, MA, 02141
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.

▼ Key Metrics (TTM)

As of Sep 30, 2026
Financials
Revenue
$49.83M
Net Income
$-72.23M
Total Assets
$219.41M
Total Equity
$84.52M
Total Debt
$56.82M
Free Cash Flow
$-110.46M
Ratios
Operating Margin
-151.7%
Net Margin
-145%
Return on Equity
-85.5%
Return on Assets
-32.9%
Current Ratio
2.82x
Debt / Equity
0.67x
FCF / Assets
-50.3%

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

Editas Medicine, Inc. generated $40.52M of revenue in fiscal 2025, with net loss of $160.06M and an operating cash outflow of $165.24M. Revenue of $40.52M sets the scale for evaluating how effectively sales translated into profit and cash during the year. Revenue was 25.4% above fiscal 2024 revenue of $32.31M, marking a year-over-year increase. The company reported diluted EPS of -$1.80, adding a shareholder-level measure to the absolute income figures considered below. A diluted share base of 88.75M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. At period end, total assets were $186.53M, framing the scale of the company’s operating and financing commitments. Revenue equaled 0.22x of total assets, indicating how much reported top-line activity the company produced relative to its period-end asset base.

Profitability

The company recorded an operating loss of $160.01M after the reported operating expense base. The operating loss equaled 394.9% of revenue, showing the scale of the operating deficit relative to sales. The bottom-line result was a net loss of $160.06M after operating, financing, tax, and other recognized items. Net margin was -395.0%, reflecting a loss equal to 395.0% of reported revenue. The company reported negative EBITDA of $154.73M, adding a pre-interest, tax, depreciation, and amortization view of the operating shortfall. The reported income-tax provision was $0.00, the amount recognized between pretax income and the final net-income result. Relative to period-end equity, the net loss represented 586.6%. The loss-to-assets relationship was 85.8%, placing the bottom-line deficit against the company’s resource base. The bottom-line deficit decreased from $237.09M in fiscal 2024 to $160.06M.

Liquidity and Capital Structure

Total assets were $186.53M, supported by $159.25M of liabilities and $27.29M of shareholder equity. Current assets were $163.90M against $46.25M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. At 3.54x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. Cash and equivalents totaled $146.65M, identifying the most liquid reported component available within the broader current-asset balance. Measured only with cash and equivalents, coverage of current liabilities was 317.1%, excluding receivables and other current assets. Total debt was $58.60M, establishing the amount of borrowing carried within the company’s capital structure. Against book equity, debt measured 2.15x, placing the company’s financial leverage in clear balance-sheet terms. Debt represented 31.4% of total assets, placing borrowing in the context of the company’s full resource base. Book equity represented 14.6% of total assets, quantifying the balance-sheet share supported by shareholder capital. Liabilities represented 85.4% of total assets, quantifying the liability-funded share of the company’s resource base. The cash-to-assets relationship was 78.6%, comparing reported cash and equivalents with the full positive asset balance. The asset base changed 45.4% from $341.59M in fiscal 2024, leaving current total assets lower year over year. Reported equity changed 79.7% from $134.27M in fiscal 2024, placing the current capital base lower year over year. Compared with $131.54M in fiscal 2024, the current cash balance moved 11.5% and finished higher.

Cash Flow and Earnings Quality

Operating activities used $165.24M of cash, resulting in an operating cash outflow for the year. Capital expenditures used $607.00K in addition to the operating cash outflow, increasing the total cash consumed by operations and investment during the period. The company recorded a $165.85M cash deficit after capital spending for the period. The free-cash-flow deficit equaled 409.3% of revenue, showing the post-investment cash shortfall relative to sales. The cash deficit after capital spending represented 88.9% of the period-end asset base. Cash absorbed by operations decreased from $210.28M in fiscal 2024 to $165.24M.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for Editas Medicine, Inc.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $40.52M $32.31M $78.12M
OPERATING EXPENSES
R&D Expense $89.95M $199.25M $177.65M
SG&A Expense $49.90M $71.99M $69.65M
Operating Income $-160.01M $-251.15M $-169.18M
NON-OPERATING INCOME / EXPENSE
Interest Expense $6.17M $2.19M -
Other Income/Expense $-2.19M $-3.00K $-1.60M
Income Tax $0 $0 $0
Net Income $-160.06M $-237.09M $-153.22M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-1.80 $-2.88 $-2.02
Diluted Shares 88.75M 82.34M 75.97M
EBITDA $-154.73M $-245.34M $-163.12M
Depreciation & Amortization $5.28M $5.81M $6.06M
Balance Sheet
ASSETS
Cash & Equivalents $146.65M $131.54M $123.65M
Short-term Investments $0 $138.37M $199.46M
Accounts Receivable $15.18M $16.27M $10.19M
Other Current Assets $2.07M $3.14M $7.53M
Current Assets $163.90M $289.32M $340.83M
PP&E (Net) $3.54M $14.50M $12.03M
Other Noncurrent Assets $2.98M $5.22M $8.59M
Noncurrent Assets $22.64M $52.27M $158.32M
Total Assets $186.53M $341.59M $499.15M
LIABILITIES
Accounts Payable $2.61M $5.49M $8.27M
Short-term Debt $5.00M $5.00M $0
Other Current Liabilities $556.00K $808.00K $283.00K
Current Liabilities $46.25M $77.23M $63.22M
Long-term Debt $53.61M $52.43M $0
Other Noncurrent Liabilities $2.82M $3.07M $1.80M
Noncurrent Liabilities $113.00M $130.09M $86.84M
Total Liabilities $159.25M $207.32M $150.06M
EQUITY
Common Stock $10.00K $8.00K $8.00K
Additional Paid-in Capital $1.66B $1.60B $1.58B
Retained Earnings $-1.63B $-1.47B $-1.23B
Accumulated OCI $0 $268.00K $198.00K
Total Equity $27.29M $134.27M $349.10M
Total Liabilities & Equity $186.53M $341.59M $499.15M
SUPPLEMENTAL
Total Debt $58.61M $57.43M $0
Shares Outstanding 97.87M 82.73M 81.77M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-165.24M $-210.28M $-132.18M
Capital Expenditures $607.00K $8.83M $4.72M
Cash from Investing $138.67M $162.15M $-3.73M
Cash from Financing $40.47M $56.03M $118.04M
Free Cash Flow $-165.85M $-219.11M $-136.90M
Beginning Cash (CFS) $135.42M $127.53M $145.40M
Net Change in Cash $13.90M $7.89M $-17.87M
Effect of FX on Cash - - -
Calculated Ending Cash $149.32M $135.42M $127.53M
Cash per BS $146.65M $131.54M $123.65M
Cash scope difference (CFS − BS) $2.67M $3.88M $3.88M
Cash per CFS $149.32M $135.42M $127.53M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is Editas Medicine, Inc.'s annual revenue?

Editas Medicine, Inc. reported $49.83M in revenue for trailing twelve months (ending September 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is Editas Medicine, Inc. profitable?

No. Editas Medicine, Inc. reported $-72.23M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.

What is Editas Medicine, Inc.'s debt level?

Editas Medicine, Inc. carries $56.82M in total debt as of trailing twelve months. Total shareholders' equity stands at $84.52M.

Does Editas Medicine, Inc. generate free cash flow?

No. Free cash flow was $-110.46M for trailing twelve months. Operating cash flow was $-110.21M.